- Home
- OPFI vs FENC Comparison
OPFI vs FENC Comparison
Compare OPFI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.57
Company Overview
Basic Information| Metric | OPFI | FENC |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 258.5M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | OPFI | FENC |
|---|---|---|
| Price | $11.16 | $7.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.75 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 558.3K | 219.0K |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $335,423,000.00 | $38,790,000.00 |
| Revenue This Year | $120.32 | N/A |
| Revenue Next Year | $10.85 | $75.22 |
| P/E Ratio | $80.84 | ★ N/A |
| Revenue Growth | ★ 28.69 | N/A |
| 52 Week Low | $6.65 | $4.68 |
| 52 Week High | $17.73 | $9.92 |
Technical Indicators
Market Signals| Indicator | OPFI | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 42.20 |
| Support Level | $10.03 | $7.35 |
| Resistance Level | $10.36 | $7.74 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 91.86 | 20.00 |
Price Performance
Historical Comparison OPFI
FENC
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.